1,476 results match your criteria Clinical breast cancer[Journal]


Adjuvant Radiation Therapy for T3N0 Breast Cancer Patients Older Than 75 Years After Mastectomy: A SEER Analysis.

Clin Breast Cancer 2018 Jun 15. Epub 2018 Jun 15.

Department of Radiation Oncology, New York Presbyterian Hospital - Weill Cornell Medicine, New York, NY. Electronic address:

Introduction: Breast cancer patients with tumors > 5 cm but without nodal disease who undergo mastectomy present a clinical challenge regarding the appropriate adjuvant treatment. Traditionally, postmastectomy radiation therapy (PMRT) was the standard of care. However, recent studies have suggested local failure rates without PMRT might be low enough to omit RT. Read More

View Article

Survival Benefit of Surgical Removal of Primary Tumor in Patients With Stage IV Breast Cancer.

Clin Breast Cancer 2018 May 28. Epub 2018 May 28.

Department of Surgery, Daerim St. Mary's Hospital, Seoul, Korea.

Background: Several studies have suggested that primary tumor removal improved overall survival for patients with stage IV breast cancer. However, the survival benefit of local treatment remains controversial. The purpose of the present study was to determine whether surgical removal of the primary tumor provides survival benefits to patients with stage IV breast cancer. Read More

View Article

Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Clin Breast Cancer 2018 Apr 7. Epub 2018 Apr 7.

Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medicine, New York, NY.

Background: Eribulin has significantly improved overall survival for patients with metastatic breast cancer who received ≥ 2 prior chemotherapy regimens for advanced disease. This trial assessed eribulin as adjuvant therapy for patients with early-stage breast cancer.

Patients And Methods: Patients with human epidermal growth factor receptor 2-negative, stage I to III breast cancer received doxorubicin 60 mg/m and cyclophosphamide 600 mg/m provided intravenously on day 1 of each 14-day cycle for 4 cycles, with pegfilgrastim on day 2, followed by 4 cycles of eribulin mesylate 1. Read More

View Article

Impact of Detection Method and Age on Survival Outcomes in Triple-Negative Breast Cancer: A Population-Based Cohort Analysis.

Clin Breast Cancer 2018 Apr 28. Epub 2018 Apr 28.

Division of Anatomic Pathology, Queen Elizabeth II Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada.

Background: Most investigations have compared triple-negative breast cancer (TNBC) to non-TNBC to elucidate clinical or epidemiologic differences between subtypes. We examined a contemporary cohort of patients with primary TNBC by detection and age at diagnosis within a population-based breast screening program to examine survival outcomes.

Patients And Methods: All women with a diagnosis of primary TNBC between January 1, 2005, and December 31, 2012, in Nova Scotia, Canada, were included. Read More

View Article

Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor.

Clin Breast Cancer 2018 Apr 19. Epub 2018 Apr 19.

Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, People's Republic of China; Department of Breast Cancer Medical Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China. Electronic address:

Introduction: Hormone receptor and human epidermal growth factor receptor 2 (HER2) status is important for breast cancer (BC) treatment. Previous studies have shown that the long-term treatment outcomes of BC are significantly impaired by the development of subsequent malignancies. Therefore, in the present study, we evaluated the effect of hormone receptor/HER2 status on subsequent malignancies in breast cancer survivors. Read More

View Article

Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.

Clin Breast Cancer 2018 May 4. Epub 2018 May 4.

Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia. Electronic address:

Purpose: Nonhematologic adverse events (AEs) of docetaxel constitute an extra burden in the treatment of cancer patients and necessitate either a dose reduction or an outright switch of docetaxel for other regimens. These AEs are frequently associated with genetic polymorphisms of genes encoding for proteins involved docetaxel disposition. Therefore, we investigated that association in Malaysian breast cancer patients. Read More

View Article

Exercise and Education Program After Breast Cancer: Benefits on Quality of Life and Symptoms at 3, 6, 12, and 24 Months' Follow-up.

Clin Breast Cancer 2018 May 19. Epub 2018 May 19.

Department of Sport and Rehabilitation Science, Liège University, Liège, Belgium; Department of Physical and Rehabilitation Medicine, Liège University Hospital, Liège, Belgium.

Background: Various clinical trials have demonstrated the benefits of physical training offered during and/or after breast cancer treatments. However, given the variety of adverse events that may be encountered, physical training could be combined with psychologic, relational, and social guidance. This kind of multidisciplinary program, as well as its long-term effects, have been little studied so far. Read More

View Article

Prognostic Significance of Mesenchymal-Epithelial Transition in Triple-Negative Breast Cancers.

Clin Breast Cancer 2018 May 7. Epub 2018 May 7.

Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address:

Introduction: The prognostic value of the mesenchymal-epithelial transition (MET) in triple-negative breast cancers (TNBCs) remains controversial. A meta-analysis of the impact of MET in TNBCs was performed by searching published data.

Methods: PubMed and Embase databases were searched for eligible literature. Read More

View Article

Hot Spot and Whole-Tumor Enumeration of CD8 Tumor-Infiltrating Lymphocytes Utilizing Digital Image Analysis Is Prognostic in Triple-Negative Breast Cancer.

Clin Breast Cancer 2018 May 7. Epub 2018 May 7.

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.

Background: CD8 tumor-infiltrating lymphocytes (TILs) have emerged as a prognostic indicator in triple-negative breast cancer (TNBC). There is debate surrounding the prognostic value of hot spots for CD8 TIL enumeration.

Methods: We compared hot spot versus whole-tumor CD8 TIL enumeration in prognosticating TNBC using immunohistochemistry on whole tissue sections and quantification by digital image analysis (Halo imaging analysis software; Indica Labs, Corrales, NM). Read More

View Article

Air Travel Safety in Postoperative Breast Cancer Patients: A Systematic Review.

Clin Breast Cancer 2018 May 17. Epub 2018 May 17.

Division of Breast Surgery, Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong SAR. Electronic address:

Air travel has long been a dilemma in post-breast cancer surgery patients. Anecdotal reports have described adverse outcomes on surgical wound, implants, and lymphedema during air travel. This review aims to evaluate the best evidence from the literature concerning the air travel safety in breast cancer patients. Read More

View Article

Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy.

Clin Breast Cancer 2018 Apr 19. Epub 2018 Apr 19.

Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

Background: Receipt of a gonadotropin-releasing hormone (GnRH) agonist has been reported to protect against ovarian failure. We sought to determine the oncologic effect of a GnRH agonist with chemotherapy for breast cancer patients.

Patients And Methods: Data from 1160 patients aged 20 to 40 years with stage I to III breast cancer who received chemotherapy from 5 hospitals in Korea from 2002 to 2012 were reviewed. Read More

View Article
April 2018
1 Read

Patterns of Distant Failure by Intrinsic Breast Cancer Subtype in Premenopausal Women Treated With Neoadjuvant Chemotherapy.

Clin Breast Cancer 2018 May 7. Epub 2018 May 7.

Department of Radiation Oncology, Stanford Cancer Institute, Stanford, CA. Electronic address:

Purpose: To identify patterns of distant failure (DF) in premenopausal women receiving neoadjuvant chemotherapy (NAC) for breast cancer.

Patients And Methods: Premenopausal patients treated with NAC between 2005 and 2015 at a single institution were retrospectively reviewed. Timing and location of local, regional, and distant metastases were described. Read More

View Article
May 2018
1 Read

Presence of S100A8/Gr1-Positive Myeloid-Derived Suppressor Cells in Primary Tumors and Visceral Organs Invaded by Breast Carcinoma Cells.

Clin Breast Cancer 2018 Apr 26. Epub 2018 Apr 26.

Department of Pharmacology, School of Medicine, Antalya, Turkey.

Background: Increased S100A8/A9 expression in Gr1-positive cells has been shown in myeloid-derived suppressor cells and may play a role in the formation of a metastatic milieu. We aimed to determine S100A8/A9 expression alone and with coexpression of Gr1 (a myeloid marker) in primary tumor and visceral tissues invaded by metastatic breast carcinoma.

Materials And Methods: Female BALB/c mice were injected with 4TLM, 4THM, and 67NR orthotopically. Read More

View Article
April 2018
4 Reads

CDK4/6 Inhibitors in Combination With Hormone Therapy for HR/HER2 Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Clin Breast Cancer 2018 May 4. Epub 2018 May 4.

Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China. Electronic address:

Background: This meta-analysis of randomized controlled trials aimed to comprehensively assess the efficacy and toxicity of cyclin-dependent kinase (CDK) 4/6 inhibitors in advanced breast cancer (ABC) with hormone-receptor positive (HR) and human epidermal growth factor receptor 2 negative (HER2) disease.

Methods: We performed a systematical search using Cochrane Library, PubMed, Embase, and Web of Science up to March 2018. Only phase 2 and 3 randomized clinical trials assessing the efficacy and toxicity of the combination regimen of CDK4/6 inhibitors plus hormone therapy compared with hormone therapy alone were eligible for this meta-analysis. Read More

View Article

Early Local Recurrence in a Patient With Encapsulated Papillary Carcinoma of the Breast.

Clin Breast Cancer 2018 May 9. Epub 2018 May 9.

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. Electronic address:

View Article

Development of a Model to Predict Invasiveness in Ductal Carcinoma In Situ Diagnosed by Percutaneous Biopsy-Original Study and Critical Evaluation of the Literature.

Clin Breast Cancer 2018 Apr 28. Epub 2018 Apr 28.

Department of Obstetrics and Gynecology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.

Background: Approximately 30% of ductal carcinoma in situ (DCIS) cases have an invasive component discovered on the final analysis that could affect surgical management. The aims of the present study were to determine the risk factors associated with the underestimation of DCIS and to develop a model to predict the probability of invasiveness.

Materials And Methods: A retrospective analysis was performed on the data for all patients with a diagnosis of DCIS found by percutaneous biopsy from January 2008 to February 2016. Read More

View Article
April 2018
1 Read

Breast Reconstruction After Mastectomy: A Survey of Surgeons' and Patients' Perceptions.

Clin Breast Cancer 2018 Apr 28. Epub 2018 Apr 28.

Reconstructive Sciences Unit, School of Medical Sciences and Hospital Universiti Sains Malaysia, Health Campus Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. Electronic address:

Background: Breast reconstruction after mastectomy is important in breast cancer care.

Materials And Methods: A cross-sectional study was designed to assess surgeons' and patients' perceptions toward breast reconstruction. Questionnaires were distributed to general and breast surgeons in East Coast Malaysian hospitals and Hospital Kuala Lumpur and to postmastectomy patients with and without breast reconstruction at the Hospital Universiti Sains Malaysia and Hospital Raja Perempuan Zainab II. Read More

View Article

Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer.

Clin Breast Cancer 2018 Apr 28. Epub 2018 Apr 28.

Department of Medical Oncology, Gold Coast University Hospital, Gold Coast, QLD, Australia.

Introduction: Maintaining the relative dose intensity (RDI) of adjuvant chemotherapy at ≥ 85% has been associated with improved treatment outcomes in early-stage breast cancer (ESBC). Increasing evidence has suggested that patients aged ≥ 65 years can maintain the optimal RDI for standard chemotherapy regimens. The present study investigated the RDI of newer adjuvant chemotherapy regimens in this demographic. Read More

View Article

Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment.

Clin Breast Cancer 2018 Apr 28. Epub 2018 Apr 28.

Deparmtent of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.

Purpose: Outcome data on hormone receptor positive (HR), human epidermal growth factor receptor 2 (HER2) nonamplified (HER2) metastatic breast cancer (MBC) treated with palbociclib after treatment with everolimus are lacking. The PALOMA-3 trial, showing benefit of palbociclib plus fulvestrant compared to fulvestrant alone in HRHER2 MBC after progression while receiving endocrine therapy excluded women previously treated with everolimus. The objective of this study was to examine outcomes of HRHER2 MBC with prior exposure to everolimus while receiving palbociclib-based therapy. Read More

View Article
April 2018
3 Reads

Body Weight and Breast Cancer: Nested Case-Control Study in Southern Brazil.

Clin Breast Cancer 2018 Apr 28. Epub 2018 Apr 28.

Hospital Moinhos de Vento, Porto Alegre, Brazil; Department of Public Health, Federal University of Health Sciences of Porto Alegre (UFCSPA), Porto Alegre, Brazil.

Background: Current studies have shown that fast weight gain may be more important than body mass index on the incidence of breast cancer. The aim of this study was to evaluate the association between body weight and breast cancer.

Patients And Methods: This was a case-control study nested in a cohort of a breast cancer mammography screening program in Southern Brazil. Read More

View Article
April 2018
1 Read

Hypofractionated Whole-Breast Irradiation With or Without Boost in Elderly Patients: Clinical Evaluation of an Italian Experience.

Clin Breast Cancer 2018 Apr 22. Epub 2018 Apr 22.

Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Purpose: To examine local control, disease-free survival (DFS), and toxicity in elderly (≥ 65 years) breast cancer patients treated with hypofractionated radiotherapy (hypo-RT) with or without a boost to the tumor bed.

Patients And Methods: The study was conducted on 752 patients treated from April 2009 to February 2017. Patients received 42. Read More

View Article
April 2018
1 Read

HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.

Clin Breast Cancer 2018 Apr 18. Epub 2018 Apr 18.

Division of Clinical Oncology, St Anna University Hospital, Ferrara, Italy. Electronic address:

Background: Infiltrating lobular carcinoma (ILC) represents about 10% of breast cancer and rarely shows overexpression of human epidermal growth factor receptor 2 (HER2). We compared biological and clinical characteristics of HER2-positive ILC versus HER2-positive infiltrating ductal carcinoma (IDC).

Patients And Methods: We retrospectively analyzed the data of 328 patients with HER2-positive pure ductal or lobular breast carcinoma, comparing clinical and biological data at diagnosis as well as outcome between the 2 histologies. Read More

View Article

Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.

Clin Breast Cancer 2018 Mar 23. Epub 2018 Mar 23.

Department of Pathology, Ewha Womans University School of Medicine, Yangcheongu, Seoul, Korea. Electronic address:

Introduction: Recently, Burstein et al identified 4 stable molecular subtypes of triple negative breast cancer (TNBC) by mRNA profiling: luminal androgen receptor (LAR), mesenchymal (MES), basal-like immune-activated (BLIA), and basal-like immune-suppressive (BLIS) types. The purpose of this study was to assess the feasibility of immunohistochemistry (IHC) surrogate panel in classifying the TNBC molecular subtypes using a large cohort of TNBC retrieved from a single institution.

Materials And Methods: IHC for androgen receptor [AR], claudin-3, E-cadherin, cytokeratin 5/6 [CK5/6], epidermal growth factor receptor [EGFR], indoleamine 2,3-dioxygenase 1 [IDO1], and Forkhead box C1 [FOXC1] were performed using the tissue microarray constructed from 200 TNBC samples. Read More

View Article

Can Gentamicin-collagen Sponges Prevent Seroma Formation Following Mastectomy?

Clin Breast Cancer 2018 Mar 9. Epub 2018 Mar 9.

Department of Surgery, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands.

Background: The aim of this study was to investigate whether gentamicin-collagen (GC) sponges can lower the incidence of seroma and surgical site infections following breast cancer surgery.

Patients And Methods: A retrospective cohort study was performed. Two consecutive cohorts of patients who underwent a mastectomy with or without an axillary lymph node dissection were compared. Read More

View Article

Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment.

Clin Breast Cancer 2018 Apr 19. Epub 2018 Apr 19.

Statistics and Data Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Purpose: To investigate the effect of body mass index (BMI) on survival in patients with breast cancer according to tumor subtype, metabolic syndrome, and systemic treatment.

Patients And Methods: We identified 5668 patients who underwent curative surgery for breast cancer between 1996 and 2013 from the clinical data of a single institution. Disease-free survival (DFS) and overall survival (OS) were calculated and compared between the patients with BMI ≥ 25 kg/m and < 25 kg/m in all patients and in specific subgroups, including tumor subtype, metabolic syndrome, and systemic treatment. Read More

View Article
April 2018
1 Read

Robot-Assisted Internal Mammary Lymph Node Chain Dissection for Breast Cancer.

Clin Breast Cancer 2018 Apr 19. Epub 2018 Apr 19.

Department of Thyroid and Breast Surgery, Jinan Military General Hospital of PLA, Jinan, China.

View Article

Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: A Retrospective Review.

Clin Breast Cancer 2018 Apr 18. Epub 2018 Apr 18.

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN.

Background: Leuprolide is a safe and effective treatment of estrogen receptor-positive premenopausal breast cancer. Data from the SOFT/TEXT trials solidified leuprolide in combination with an aromatase inhibitor as an effective hormonal treatment for premenopausal breast cancer. However, the efficacy of monthly leuprolide depot compared to leuprolide depot every 3 months in combination with an aromatase inhibitor in this patient population is unclear. Read More

View Article
April 2018
1 Read

Beyond BRCA: A Case Series Examining the Advent of Multigene Panel Testing.

Clin Breast Cancer 2018 Apr 6. Epub 2018 Apr 6.

Michigan State University College of Human Medicine, East Lansing, MI.

View Article

Tumor Resection Margin Definitions in Breast-Conserving Surgery: Systematic Review and Meta-analysis of the Current Literature.

Clin Breast Cancer 2018 Apr 13. Epub 2018 Apr 13.

Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands; MIRA Institute, University of Twente, Enschede, The Netherlands.

Worldwide, various guidelines recommend what constitutes an adequate margin of excision for invasive breast cancer or for ductal carcinoma-in-situ (DCIS). We evaluated the use of different tumor resection margin guidelines and investigated their impact on positive margin rates (PMR) and reoperation rates (RR). Thirteen guidelines reporting on the extent of a positive margin were reviewed along with 31 studies, published between 2011 and 2016, reporting on a well-defined PMR. Read More

View Article

Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.

Clin Breast Cancer 2018 Apr 10. Epub 2018 Apr 10.

Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address:

Purpose: To identify whether a certain group of breast ductal carcinoma-in-situ (DCIS) patients can be treated with breast-conserving surgery (BCS) alone; to analyze the clinicopathologic features of DCIS and tamoxifen administration in patients treated with BCS who developed ipsilateral breast tumor recurrence (IBTR).

Patients And Methods: Data for 375 women with breast DCIS who underwent BCS at our institute between June 2003 and October 2010 were analyzed. The patients were divided into different categories according to the recurrence risk predicted using the California/Van Nuys Prognostic Index (USC/VNPI) score (4-6, 7-9, and 10-12), Eastern Cooperative Oncology Group (ECOG) E5194 criteria, or combined risk features with USC/VNPI score and ECOG E5194 criteria. Read More

View Article

Impact of Adjuvant Anthracycline-Based and Taxane-Based Chemotherapy on Plasma VEGF Levels and Cognitive Function in Breast Cancer Patients: A Longitudinal Study.

Clin Breast Cancer 2018 Apr 6. Epub 2018 Apr 6.

Department of Pharmacy, National University of Singapore, Singapore; Oncology Pharmacy, National Cancer Centre Singapore, Singapore; Duke-NUS Graduate Medical School Singapore, Singapore. Electronic address:

Background: Vascular endothelial growth factor (VEGF) has been shown to induce neurogenesis in the brain and yield neuroprotective effects. It is hypothesized that chemotherapy reduces circulating VEGF levels and leads to cognitive decline among patients. This multicenter longitudinal study aimed to evaluate the impact of chemotherapy on VEGF levels and the association between VEGF levels and cognitive function. Read More

View Article
April 2018
2 Reads

Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis.

Clin Breast Cancer 2018 Mar 30. Epub 2018 Mar 30.

Pharmerit International, Bethesda, MD.

Background: In this analysis we compared quality-adjusted survival outcomes between nab-paclitaxel (nab-P) and standard paclitaxel (Pac) using data from the nab-P phase III registration trial in metastatic breast cancer.

Patients And Methods: Quality-adjusted overall survival was estimated using the quality-adjusted time without symptoms or toxicity (Q-TWiST) approach. Overall survival was partitioned into time without progression/Grade ≥ 3 adverse events (AEs) toxicity (TWiST), time with Grade ≥ 3 AE toxicity (TOX), and time after relapse (REL). Read More

View Article
March 2018
1 Read

Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy.

Clin Breast Cancer 2018 Mar 15. Epub 2018 Mar 15.

Division of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. Electronic address:

Background: Neoadjuvant systemic therapy (NST) is performed to increase the rate of breast-conserving surgery in advanced breast cancer patients. Although magnetic resonance imaging (MRI) is accurate in predicting residual cancer, if calcification remains, the issue of whether to perform the surgery on the basis of the residual tumor prediction range in mammography (MMG) or MRI has not yet been elucidated. This study aimed to estimate the accuracy of predicting residual tumor after NST for residual microcalcification on mammographic and enhancing lesion on MRI. Read More

View Article
March 2018
3 Reads

The Challenge of Evaluating Adnexal Masses in Patients With Breast Cancer.

Clin Breast Cancer 2018 Mar 12. Epub 2018 Mar 12.

Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil. Electronic address:

This narrative literature review addresses the problem of an adnexal mass discovered during the course of breast cancer (BC) care, which may represent a benign condition, a metastatic process, or a primary ovarian cancer (OC), clinical scenarios associated with distinct physiopathology and prognosis. Furthermore, the coexistence of BC and OC in the same patient may be owing to a hereditary disorder, deserving specific management strategies and counseling. The initial detection and evaluation of an adnexal mass in a patient with BC requires a high index of suspicion, and the initial workup should include a thorough medical history and physical examination, measurement of tumor markers, complete blood count, and imaging tests. Read More

View Article

Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.

Clin Breast Cancer 2018 Mar 15. Epub 2018 Mar 15.

Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY. Electronic address:

Background: Overexpression and activation of tyrosine kinase Src has been linked to breast carcinogenesis and bone metastases. We showed the feasibility of combining the SRC inhibitor dasatinib with weekly paclitaxel in patients with metastatic breast cancer (MBC) and herein report the subsequent phase II trial.

Patients And Methods: Patients had received ≤ 2 chemotherapy regimens for measurable, HER2-negative MBC. Read More

View Article

Cabazitaxel Plus Lapatinib as Therapy for HER2 Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study.

Clin Breast Cancer 2018 Mar 8. Epub 2018 Mar 8.

Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN.

Background: Lapatinib is an oral small molecule tyrosine kinase epidermal growth factor receptor-1/HER2 inhibitor that crosses the blood-brain barrier and is active against central nervous system (CNS) metastases. Cabazitaxel is a taxoid that is effective against taxane-resistant metastatic breast cancer (MBC) and has distinguished itself by its ability to cross the blood-brain barrier. The present phase II study (ClinicalTrials. Read More

View Article
March 2018
2 Reads

Electrochemotherapy for Breast Cancer-Results From the INSPECT Database.

Clin Breast Cancer 2018 Mar 14. Epub 2018 Mar 14.

Department of Oncology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark; Center for Experimental Drug and Gene Electrotransfer (C*EDGE), Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Background: Cutaneous recurrence from breast cancer can pose a clinical challenge. It might be the only disease site, or could be part of disseminated disease, and often profoundly affects quality of life. Electrochemotherapy is a palliative treatment using electric pulses to locally permeabilize tumor cells and thereby significantly increase bleomycin cytotoxicity. Read More

View Article
March 2018
3 Reads

Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers.

Clin Breast Cancer 2018 Feb 20. Epub 2018 Feb 20.

Department of Hereditary Cancer Clinic, Cancer Prevention Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea; Department of Surgery, Yonsei University College of Medicine, Seoul, Korea. Electronic address:

Introduction: We investigated the relative risk of breast and ovarian cancers related to the putative functional domain regions, obesity, and parity among Korean BRCA1/2 mutation carriers.

Patients And Methods: We analyzed the clinical characteristics, cancer history, and mutations according to the putative functional domain of BRCA proteins among 229 women with BRCA1/2 mutations who were treated at Yonsei Cancer Center, Severance Hospital between January 2009 and March 2017.

Results: Twenty-two carriers (18. Read More

View Article
February 2018
1 Read

Breast Cancer and Ovulation Induction Treatments.

Clin Breast Cancer 2018 Mar 15. Epub 2018 Mar 15.

Shahid Akbar-Abadi Hospital IVF Center, IVF Department, Iran University of Medical Sciences, Tehran, Iran. Electronic address:

Background: This study was performed to determine whether the use of ovulation induction drugs in treatment of infertility have a significant effect on the risk of breast cancer.

Patients And Methods: This case control study (928 cases, 928 controls), was performed in the gynecology and oncology clinics of Shahid Beheshti University of Medical Sciences between 2011 and 2013. Data were collected via in-person interviews using a questionnaire, which included demographic and gynecologic information. Read More

View Article
March 2018
1 Read

Specialized Second Opinion Interpretations of Breast Imaging: Impact on Additional Workup and Management.

Clin Breast Cancer 2018 Mar 16. Epub 2018 Mar 16.

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Background: Women with breast imaging often seek second opinions at tertiary care centers. Our study measures the frequency of discrepancy between initial and second opinion breast imaging recommendations and evaluates the impact on patient management.

Materials And Methods: A retrospective chart review was conducted on 504 consecutive patients with second opinion breast radiology interpretations performed by 6 sub-specialized breast radiologists at a dedicated cancer center from January 1, 2014 through September 1, 2014. Read More

View Article
March 2018
6 Reads

Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer.

Clin Breast Cancer 2018 Feb 16. Epub 2018 Feb 16.

Duke University Medical Center, Durham, NC.

Background: The effects of chemotherapy dose intensity on patient outcomes in advanced cancer are not well understood. We studied the association between chemotherapy relative dose intensity (RDI) and overall survival (OS) among patients with advanced breast or ovarian cancer.

Patients And Methods: This retrospective cohort study included adults with advanced breast or ovarian cancer who received first-line myelosuppressive chemotherapy (January 2007 to December 2010) in US Oncology Network community practices. Read More

View Article
February 2018
1 Read

Invasive Breast Carcinoma Tumor Size on Core Needle Biopsy: Analysis of Practice Patterns and Effect on Final Pathologic Tumor Stage.

Clin Breast Cancer 2018 Mar 5. Epub 2018 Mar 5.

Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Department of Pathology and Cell Biology, University of South Florida, Tampa, FL.

Introduction: In the absence of nodal metastasis, pathologic tumor (pT) size remains one of the most important factors in adjuvant treatment decisions and patient prognosis in breast cancer. The aim of this study was to evaluate the effect of core needle biopsy (CNB) tumor size on final pT stage.

Materials And Methods: Our information system was searched to identify all patients who underwent excisional procedures for invasive breast carcinoma from January 1 2014 to December 31, 2015. Read More

View Article
March 2018
1 Read

Prospective Study of Breast Radiation Dermatitis.

Clin Breast Cancer 2018 Mar 15. Epub 2018 Mar 15.

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

Background: Despite clear benefits of radiotherapy (RT) for breast cancer, there are numerous side effects. Radiation dermatitis has a significant impact on quality of life and can result in treatment interruptions or cessation. The purpose of this study was to prospectively follow breast radiation dermatitis and determine trends including peak toxicity. Read More

View Article
March 2018
2 Reads

Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.

Clin Breast Cancer 2018 Feb 24. Epub 2018 Feb 24.

Duke Cancer Institute, Durham, NC; Department of Surgery, Duke University, Durham, NC.

Background: Stromal tumor-infiltrating lymphocytes (TILs) might predict pathologic complete response (pCR) in patients with HER2-positive (HER2) breast cancer treated with trastuzumab (H). Docetaxel (T), carboplatin (C), H, and pertuzumab (P) have immune-modulating effects. Pre- and post-treatment immune biomarkers in cancers treated with neoadjuvant TCH with or without P are lacking. Read More

View Article
February 2018
2 Reads

Corneal Changes in Trastuzumab Emtansine Treatment.

Clin Breast Cancer 2018 Mar 12. Epub 2018 Mar 12.

Department of Medical Oncology, Ghent University Hospitals, Ghent, Belgium.

View Article
March 2018
2 Reads

Bone Metastasis in Advanced Breast Cancer: Analysis of Gene Expression Microarray.

Clin Breast Cancer 2018 Mar 8. Epub 2018 Mar 8.

Department of Public Health, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.

Background: Approximately 30% to 40% of breast cancer recurrences involve bone metastasis (BM). Certain genes have been linked to BM; however, none have been able to predict bone involvement. In this study, we analyzed gene expression profiles in advanced breast cancer patients to elucidate genes that can be used to predict BM. Read More

View Article
March 2018
1 Read

Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.

Clin Breast Cancer 2018 Mar 8. Epub 2018 Mar 8.

Division of Breast and Endocrine, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan. Electronic address:

Introduction: Although eribulin and nab-paclitaxel are chemotherapy agents widely used for locally advanced or metastatic breast cancer (MBC), their predictive factors remain unknown. Because the absolute neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic factor for early-stage breast cancer, we investigated its usefulness in terms of the eribulin or nab-paclitaxel treatment efficacy for MBC.

Patients And Methods: A total of 85 patients with MBC treated with eribulin (n = 59) or nab-paclitaxel (n = 26) were recruited. Read More

View Article
March 2018
1 Read

Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study.

Clin Breast Cancer 2018 Apr 31;18(2):175-183. Epub 2018 Jan 31.

Department of Obstetrics and Gynecology, LMU Munich, Munich, Germany.

Background: In addition to established prognostic factors, individual lifestyle-associated factors, such as obesity, physical activity, and diet, seem to modulate the course of breast cancer. The aim of this analysis was to evaluate the influence of weight changes during adjuvant chemotherapy on outcome in a large multicenter prospectively randomized trial.

Patients And Methods: The ADEBAR trial compares a sequential chemotherapy consisting of epirubicin/cyclophosphamide followed by docetaxel to an epirubicin/5-fluorouracil/cyclophosphamide regimen in patients with lymph node-positive early breast cancer. Read More

View Article
April 2018
1 Read

Proof-of-Concept Study of 3-D-Printed Mold-Guided Breast-Conserving Surgery in Breast Cancer Patients.

Clin Breast Cancer 2018 Feb 20. Epub 2018 Feb 20.

Shanghai Sunshine Digital Medical Co Ltd, Shanghai, China.

Purpose: In this proof-of-concept study, we proposed 3-D-printed mold-guided breast-conserving surgery (BCS) in breast cancer patients.

Patients And Methods: Pathologically confirmed and eligible breast cancer patients received magnetic resonance imaging examinations before BCS. The information on the shape, size, and location of the tumor relative to the nipple was extracted and analyzed. Read More

View Article
February 2018
1 Read

Triple Negative Apocrine Carcinomas as a Distinct Subtype of Triple Negative Breast Cancer: A Case-control Study.

Clin Breast Cancer 2018 Mar 2. Epub 2018 Mar 2.

Oncology Department, Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.

Background: Invasive triple negative apocrine carcinoma (TNAC) of the breast is a rare type of triple negative breast cancer. Several studies reported significantly distinct prognosis for TNAC when compared with most of the non-apocrine triple negative (NATN) tumors. This is a case-control study reporting onoutcomes from our long-term single-center experience. Read More

View Article
March 2018
2 Reads